Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | PTPRA | P18433 | 1/20 | 0.65 |
| ▸ | PTPRB | P23467 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.54 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pontacyl Violet 6R SCHEMBL10080484 | 1.00 | CYP1A2 (1.00) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| Pontacyl Violet 6R SCHEMBL12282563 | 1.00 | CYP1A2 (1.00) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL60352 | 0.89 | CYP1A2 (0.80) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL60351 | 0.89 | CYP1A2 (0.80) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL29767885 | 0.89 | CYP1A2 (0.80) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL11227186 | 0.89 | CYP1A2 (0.80) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL11227192 | 0.89 | CYP1A2 (0.80) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL15181277 | 0.89 | CYP1A2 (0.79) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL11763985 | 0.87 | CYP1A2 (0.79) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL70833 | 0.86 | CYP1A2 (0.76) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332256-A1 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | UNIV JOHNS HOPKINS (US) | 2023-10-19 | — | — | US | claimed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | claimed |
| US-12577571-B2 | Mutant DNase1L3 with improved serum half-life | TEXAS TECH UNIVERSITY SYSTEM (US) | 2026-03-17 | — | — | US | disclosed |
| US-12336973-B2 | Cancer therapeutic compositions and methods targeting DNAse1L3 | PROVIDENCE HEALTH & SERVICES—OREGON (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240271184-A1 | LOW PH COMPOSITION AND METHOD FOR STABILIZING NUCLEIC ACIDS IN BIOLOGICAL SAMPLES | DNA GENOTEK INC. (CA) | 2024-08-15 | — | — | US | disclosed |
| EP-4352249-A1 | LOW PH COMPOSITION AND METHOD FOR STABILIZING NUCLEIC ACIDS IN BIOLOGICAL SAMPLES | DNA Genotek Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-20230332256-A1 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | UNIV JOHNS HOPKINS (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230241015-A1 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2023-08-03 | — | — | US | disclosed |
| CN-112946140-B | Method for detecting water-soluble anion synthetic pigment in food | 广州市食品检验所（广州市酒类检测中心） | 2023-03-21 | — | — | CN | disclosed |
| CN-115669544-A | New method for culturing pepper anther based on embryoid approach and ploidy identification of plant | 安徽农业大学 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022256930-A1 | LOW PH COMPOSITION AND METHOD FOR STABILIZING NUCLEIC ACIDS IN BIOLOGICAL SAMPLES | DNA GENOTEK INC. (CA) | 2022-12-15 | — | — | WO | disclosed |
| US-20220380780-A1 | Mutant Dnase1L3 with Improved Serum Half-Life | TEXAS TECH UNIVERSITY SYSTEM | 2022-12-01 | — | — | US | disclosed |
| WO-2022188373-A1 | METHOD FOR DETECTING WATER-SOLUBLE ANIONIC SYNTHETIC PIGMENT IN FOOD | 广州市食品检验所（广州市酒类检测中心） | 2022-09-15 | — | — | WO | disclosed |
| EP-4041880-A1 | MUTANT DNASE1L3 WITH IMPROVED SERUM HALF-LIFE | Texas Tech University System (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022067032-A9 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022067032-A1 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577571-B2 | Mutant DNase1L3 with improved serum half-life | DNASE1L3, DNASE1, UPF1 | CYP1A2 4229/4885MAPK1 4319/4885CYP2C9 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.